French biotechnology company EVerZom has closed a €10 million funding round to support clinical development of its exosome-based therapeutic platform, with lead candidate EVerGel set to enter human trials in 2026 for treatment of complex perianal fistulas in Crohn’s disease.
Nabsys 2.0, LLC presented data on its OhmX™ Platform at the American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts, from 14-18 October 2025. The presentations demonstrated applications of electronic genome mapping (EGM) technology in multiple disease states, including interstitial cystitis/bladder pain syndrome, hematological malignancies, and repeat expansion disorders.
SPT Labtech (Melbourn, UK) and 10x Genomics (Pleasanton, California) have established a strategic partnership aimed at automating single cell research workflows.
Celonic Group, a biologics contract development and manufacturing organisation based in Basel, Switzerland, has entered into a strategic alliance with CARBOGEN AMCIS to establish an end-to-end platform for antibody-drug conjugate (ADC) production. The collaboration combines Celonic’s upstream biologics capabilities with CARBOGEN AMCIS’s downstream expertise in payload synthesis, conjugation chemistry, and sterile fill-finish operations.
UK laboratory professionals are increasingly using artificial intelligence tools without adequate understanding of their functionality or associated risks, according to a new industry report examining AI implementation in scientific research environments.
Polpharma Group, a major pharmaceutical manufacturer serving Central and Eastern Europe and Central Asia, has confirmed a planned leadership transition effective 1 January 2026. Markus Sieger will step down as chief executive officer after ten years of service, with Sebastian Szymanek succeeding him in the role.
What is multiple myeloma? Multiple myeloma (also called myeloma) is the over-proliferation of abnormal plasma cells (which normally make antibodies) in the bone marrow (Figs 1&2).
Avoid the challenges of traditional PBMC isolation.
Chronic kidney disease (CKD) affects more than 850 million individuals worldwide and represents a major public health challenge. Despite its high prevalence, CKD is frequently underdiagnosed due to its asymptomatic nature and slow progression. Early detection is essential to prevent irreversible kidney damage and improve clinical outcomes. Urinary albumin is one of several markers used […]
TRIMERO Diagnostics offers, under the brand KLoneus®, IVD CE marked nephelometric assays for testing FREE LIGHT CHAINS (FLC) on Beckman Coulter’s IMMAGE® Immunochemical Systems and Siemens’ BN™ nephelometric systems.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.